Mobile

An open–label Phase 2 Trial of Pegylated Liposomal Doxorubicin and rIL-21 in Ovarian Cancer Patients with Persistent or Progressive Disease after, or Relapse within One Year of, Completion of Standard...

Update Il y a 4 ans
Reference: EUCTR2007-001506-25

An open–label Phase 2 Trial of Pegylated Liposomal Doxorubicin and rIL-21 in Ovarian Cancer Patients with Persistent or Progressive Disease after, or Relapse within One Year of, Completion of Standard First Line Therapy

Woman Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To determine a safe dose of rIL-21 in combination with PLD, and to assess the efficacy of this combination in terms of overall response rate (RR).

Inclusion criteria

  • advanced epithelial Ovarian Cancer stage IIB-IV

Links